Barclays maintains Tenet Healthcare at Overweight, raises price target to $297 from $271

Barclays kept Tenet Healthcare's rating at Overweight and increased its price target to $297 from $271, suggesting an 11.4% upside from the Nov 3 close of $266.69. Recent analyst price targets for the company range from $300 to $342.

Original reporting
Published Nov 4, 2026, 6:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Tenet Healthcare at Overweight, raises price target to $297 from $271 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade may attract institutional buying and support the stock price.

02

Market read

A fresh analyst target can influence short‑term price action for TEN.

03

What to watch

No new operational data; price move depends on broader market sentiment.

Relevance 6/10Novelty 5/10Timing: pre‑market today

Background

Barclays maintains an Overweight rating on Tenet Healthcare, updating its valuation.

Market effects

May lift sentiment in the healthcare services sector.

US healthcare stocks could see modest gains.

Limited to US markets.

Counterpoint

Target raise could be premature if earnings miss expectations.

Key entities

  • Barclays

    Equity research firm providing the rating and target.

  • Tenet Healthcare

    U.S. healthcare services provider.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.